{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Developmental+Defect&page=27",
    "query": {
      "condition": "Developmental Defect",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 10802,
    "total_pages": 1081,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Developmental+Defect&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Developmental+Defect&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T12:49:02.292Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02139306",
      "title": "Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Ataluren (PTC124®)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PTC Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 279,
      "start_date": "2014-08",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2020-05-14",
      "last_synced_at": "2026-10-24T12:49:02.292Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Long Beach, California + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02139306"
    },
    {
      "nct_id": "NCT02314377",
      "title": "Bevacizumab Therapy for Brain Arteriovenous Malformation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Arteriovenous Malformation"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 2,
      "start_date": "2016-06",
      "completion_date": "2019-12-01",
      "has_results": false,
      "last_update_posted_date": "2020-03-03",
      "last_synced_at": "2026-10-24T12:49:02.292Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02314377"
    },
    {
      "nct_id": "NCT02392195",
      "title": "Brain Characteristics Noted Prior to and Following Treatment",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Nonsynostotic Plagiocephaly"
      ],
      "interventions": [
        {
          "name": "Non-interventional",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "8 Months",
        "sex": "ALL",
        "summary": "Up to 8 Months"
      },
      "enrollment_count": 10,
      "start_date": "2013-02",
      "completion_date": "2020-09",
      "has_results": true,
      "last_update_posted_date": "2020-12-10",
      "last_synced_at": "2026-10-24T12:49:02.292Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02392195"
    },
    {
      "nct_id": "NCT04140695",
      "title": "Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Tradipitant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanda Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 87,
      "start_date": "2019-10-21",
      "completion_date": "2020-10-14",
      "has_results": true,
      "last_update_posted_date": "2024-05-14",
      "last_synced_at": "2026-10-24T12:49:02.292Z",
      "location_count": 51,
      "location_summary": "Hoover, Alabama • Tempe, Arizona • Encino, California + 43 more",
      "locations": [
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04140695"
    },
    {
      "nct_id": "NCT01646411",
      "title": "300 Antibody Diagnostic Test Kit",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Bacterial Infections",
        "Acute Viral Infections"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "The Plasma Source",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 300,
      "start_date": "2012-08",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2012-07-20",
      "last_synced_at": "2026-10-24T12:49:02.292Z",
      "location_count": 1,
      "location_summary": "Southampton, Pennsylvania",
      "locations": [
        {
          "city": "Southampton",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01646411"
    },
    {
      "nct_id": "NCT02234934",
      "title": "Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Granulomatous Disease, Chronic, X-linked"
      ],
      "interventions": [
        {
          "name": "Lentiviral G1XCGD Gene Therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "23 Months",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "23 Months and older · Male only"
      },
      "enrollment_count": 10,
      "start_date": "2015-10-29",
      "completion_date": "2024-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-02",
      "last_synced_at": "2026-10-24T12:49:02.292Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Bethesda, Maryland • Boston, Massachusetts",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02234934"
    },
    {
      "nct_id": "NCT04468919",
      "title": "Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis",
        "Brainstem Stroke",
        "Muscular Dystrophies",
        "Parkinson's Disease and Parkinsonism",
        "Multiple System Atrophy",
        "Brain Tumor Adult",
        "Spinal Cord Injuries",
        "Locked-in Syndrome"
      ],
      "interventions": [
        {
          "name": "BCI-FIT multi-modal access",
          "type": "BEHAVIORAL"
        },
        {
          "name": "BCI-FIT adaptive signal modeling",
          "type": "BEHAVIORAL"
        },
        {
          "name": "BCI-FIT active querying",
          "type": "BEHAVIORAL"
        },
        {
          "name": "BCI-FIT language modeling",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 55,
      "start_date": "2022-07-15",
      "completion_date": "2025-05-05",
      "has_results": false,
      "last_update_posted_date": "2025-05-16",
      "last_synced_at": "2026-10-24T12:49:02.292Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04468919"
    },
    {
      "nct_id": "NCT00744692",
      "title": "Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Malignant Disorders",
        "Immunodeficiencies",
        "Congenital Marrow Failures",
        "Hemoglobinopathies",
        "Inborn Errors of Metabolism",
        "Sickle Cell",
        "Thalassemia",
        "Lysosomal Storage Disease"
      ],
      "interventions": [
        {
          "name": "Unrelated Umbilical Cord Blood Transplant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Reduced Intensity Conditioning",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 22,
      "start_date": "2008-10",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2014-08-13",
      "last_synced_at": "2026-10-24T12:49:02.292Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00744692"
    },
    {
      "nct_id": "NCT00895934",
      "title": "Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Acute Megakaryoblastic Leukemia (M7)",
        "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)",
        "Adult Acute Monoblastic Leukemia (M5a)",
        "Adult Acute Monocytic Leukemia (M5b)",
        "Adult Acute Myeloblastic Leukemia With Maturation (M2)",
        "Adult Acute Myeloblastic Leukemia Without Maturation (M1)",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Adult Acute Myelomonocytic Leukemia (M4)",
        "Adult Erythroleukemia (M6a)",
        "Adult Pure Erythroid Leukemia (M6b)",
        "Recurrent Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "vorinostat",
          "type": "DRUG"
        },
        {
          "name": "gemtuzumab ozogamicin",
          "type": "DRUG"
        },
        {
          "name": "azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2009-05",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2019-05-23",
      "last_synced_at": "2026-10-24T12:49:02.292Z",
      "location_count": 4,
      "location_summary": "Stanford, California • Bremerton, Washington • Seattle, Washington",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Bremerton",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00895934"
    },
    {
      "nct_id": "NCT03311334",
      "title": "A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Renal Cell Carcinoma (RCC)",
        "Urothelial Carcinoma",
        "Primary Peritoneal Cancer",
        "Platinum-resistant Ovarian Cancer (PROC)",
        "Serous Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "DSP-7888 Dosing Emulsion",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2017-12-14",
      "completion_date": "2022-11-29",
      "has_results": true,
      "last_update_posted_date": "2024-04-18",
      "last_synced_at": "2026-10-24T12:49:02.292Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03311334"
    }
  ]
}